Strategic Investment Boston Scientific previously invested in Millipede and acquired a portion of shares for a substantial sum, signaling strong validation of the IRIS Transcatheter Annuloplasty Ring System and potential for future collaboration or licensing deals.

Clinical Milestone Millipede has progressed to first-in-human studies and has a clinical development history, indicating near-term opportunities for clinical trial partnerships, investigator-initiated studies, or co-development arrangements with larger medtech players or contract research organizations.

Acquisition Interest A strategic partner or buyer in the cath/mitral-tricuspid space could be a fit given Millipede’s focus on transcatheter annuloplasty, suggesting outreach to major cardiology device manufacturers and private equity buyers looking for late-stage or near-market assets.

Low Revenue, High Potential With revenues under one million but substantial funding raised, there is room to position Millipede as a co-development or milestone-based commercialization partner for valve repair therapies, especially for regulatory-pathway support and share of royalties.

Targeted Collaboration Given Millipede’s Santa Rosa location and specific mitral/tricuspid device focus, identify regional or national KOLs, hospitals, and distributors in the transcatheter valve space to pilot the IRIS system, as well as potential OEM or manufacturing partners to scale production.